NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 294 filers reported holding NEKTAR THERAPEUTICS in Q3 2019. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,195 | +6.2% | 20,475 | +2.6% | 0.00% | – |
| Q2 2023 | $11,483 | -49.1% | 19,963 | -37.8% | 0.00% | – |
| Q1 2023 | $22,564 | -75.4% | 32,101 | -20.9% | 0.00% | – |
| Q4 2022 | $91,724 | -29.4% | 40,586 | -0.0% | 0.00% | – |
| Q3 2022 | $130,000 | -3.0% | 40,595 | +15.4% | 0.00% | – |
| Q2 2022 | $134,000 | -4.3% | 35,182 | +3.8% | 0.00% | – |
| Q1 2022 | $140,000 | -31.0% | 33,889 | +125.4% | 0.00% | – |
| Q4 2021 | $203,000 | -25.4% | 15,035 | -0.9% | 0.00% | – |
| Q3 2021 | $272,000 | +4.2% | 15,164 | -0.4% | 0.00% | – |
| Q2 2021 | $261,000 | -15.3% | 15,225 | -1.1% | 0.00% | – |
| Q1 2021 | $308,000 | +18.0% | 15,390 | +0.4% | 0.00% | – |
| Q4 2020 | $261,000 | +8.3% | 15,327 | +5.7% | 0.00% | – |
| Q3 2020 | $241,000 | -30.5% | 14,504 | -3.1% | 0.00% | – |
| Q2 2020 | $347,000 | -79.1% | 14,963 | -83.9% | 0.00% | -100.0% |
| Q1 2020 | $1,660,000 | +244.4% | 92,974 | +316.0% | 0.00% | 0.0% |
| Q4 2019 | $482,000 | +1105.0% | 22,349 | +919.1% | 0.00% | – |
| Q3 2019 | $40,000 | -55.1% | 2,193 | -12.2% | 0.00% | – |
| Q2 2019 | $89,000 | +3.5% | 2,498 | -2.1% | 0.00% | – |
| Q1 2019 | $86,000 | +2.4% | 2,551 | +0.3% | 0.00% | – |
| Q4 2018 | $84,000 | -46.2% | 2,543 | -0.7% | 0.00% | – |
| Q3 2018 | $156,000 | +8.3% | 2,560 | -13.2% | 0.00% | – |
| Q2 2018 | $144,000 | -61.0% | 2,949 | -15.1% | 0.00% | -100.0% |
| Q1 2018 | $369,000 | +334.1% | 3,474 | +143.4% | 0.00% | – |
| Q4 2017 | $85,000 | +3.7% | 1,427 | -58.1% | 0.00% | – |
| Q3 2017 | $82,000 | +22.4% | 3,407 | 0.0% | 0.00% | – |
| Q2 2017 | $67,000 | -15.2% | 3,407 | +1.7% | 0.00% | – |
| Q1 2017 | $79,000 | +119.4% | 3,349 | +15.2% | 0.00% | – |
| Q4 2016 | $36,000 | -23.4% | 2,908 | +5.9% | 0.00% | – |
| Q3 2016 | $47,000 | +30.6% | 2,747 | +7.2% | 0.00% | – |
| Q2 2016 | $36,000 | +2.9% | 2,563 | +2.0% | 0.00% | – |
| Q1 2016 | $35,000 | -10.3% | 2,512 | +8.4% | 0.00% | – |
| Q4 2015 | $39,000 | +69.6% | 2,318 | +10.7% | 0.00% | – |
| Q3 2015 | $23,000 | – | 2,094 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |